Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience

SIMPLE SUMMARY: KRAS gene mutations are among the most common oncogenic lesions in NSCLC patients. For many years, they were considered “incurable”. This is now changing and therapeutic options are available for NSCLC patients with mutated KRAS. It is likely that the effectiveness of immunotherapy i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmielewska, Izabela, Krawczyk, Paweł, Grenda, Anna, Wójcik-Superczyńska, Magdalena, Krzyżanowska, Natalia, Gil, Michał, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378665/
https://www.ncbi.nlm.nih.gov/pubmed/37509393
http://dx.doi.org/10.3390/cancers15143732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378665/
https://www.ncbi.nlm.nih.gov/pubmed/37509393
http://dx.doi.org/10.3390/cancers15143732

Ejemplares similares